Scarring Alopecia and Sclerodermatous Changes of the Scalp in a Patient with Hepatitis C Infection

Hepatitis C virus (HCV) is a common cause of chronic hepatitis and is frequently associated with extrahepatic disease. Recently, cutaneous disorders have been a presenting manifestation of HCV infection. Porphyria cutanea tarda (PCT) is one of the cutaneous diseases associated with hepatitis C. PCT manifests in an acute form with tense bullae and erosions and in a chronic form with milia, scarring, and sclerodermatous changes. HCV has also been implicated as a cause of vasculitis through immune complex deposition. We report a patient in whom HCV was associated with sclerodermoid PCT and a medium vessel vasculitis. This case underscores the importance of HCV and its potential cutaneous manifestations, as well as the importance of recognizing cutaneous manifestations of internal disease that may be the first clue to diagnosis of HCV.

AUTHOR: Jackson JM, Callen JP, University of Louisville Division of Dermatology, Kentucky 40202, USA.; SOURCE: J Am Acad Dermatol 1998 Nov;39(5 Pt 2):824-6

Hepatitis C Primer Home

What is Hepatitis How is Hepatitis Transmitted

Long-term Prognosis

Complications of HCV Liver Biopsy Treatment Info (Interferon, Herbal, etc) Lab Tests (PCR, Genotype,etc.) Nutrition & Alternative Info

Newsletter

Patient Information (Support Groups, Doctor Listing, etc) Related Webpages Transplant Info Site Search HCV Webrings Guestbook FAQ & Disclaimers

News and Updates

15 Tips for Managing Interferon-Ribavirin Side Effects
Finding new ways to manage the side effects of Hepatitis C combination therapy adds to a person’s likelihood of conquering the virus....

New Mexico Offers Free Hepatitis C Hotline
Finally being recognized as the widespread, public health problem that it is, the New Mexico Department of Health has taken a giant step forward to help people with Hepatitis C. By launching a new, toll-free phone number, locals concerned about...

Highly Effective Against HCV Genotype 1
When tested on people with Hepatitis C genotype 1, R7128 proved to be an effective addition to combination therapy after just four weeks' time. In addition to its anti-viral effect, polymerase inhibitor R7128 received good marks for safety and minimal...